DCVC Bio

← Back to your selection

All recorded activity

Rounds participated in: 3
Confirmed lead rounds: —
New companies: 3
Funding in participating rounds: $248.4M

By stage

Series A2

Series B1

By primary sector

Biotech3

By country

United States3

Rounds

3 in all activity

Jun 21

Syntax Bio

Develops cell therapies using proprietary Cellgorithm platform for regenerative medicine

$14.4MSeries A+

Role not disclosed

May 4

Latus Bio, Inc.

Engineers scalable AAV gene therapies for CNS and rare diseases including Huntington's disease and CLN2

$97MSeries A

Role not disclosed

Apr 8

Sidewinder Therapeutics

Develops next-generation bispecific ADCs for cancer treatment

$137MSeries B

Role not disclosed

← Back to your selection

All recorded activity

Rounds participated in: 3
Confirmed lead rounds: —
New companies: 3
Funding in participating rounds: $248.4M

By stage

Series A2

Series B1

By primary sector

Biotech3

By country

United States3

Rounds

3 in all activity

Jun 21

Syntax Bio

Develops cell therapies using proprietary Cellgorithm platform for regenerative medicine

$14.4MSeries A+

Role not disclosed

May 4

Latus Bio, Inc.

Engineers scalable AAV gene therapies for CNS and rare diseases including Huntington's disease and CLN2

$97MSeries A

Role not disclosed

Apr 8

Sidewinder Therapeutics

Develops next-generation bispecific ADCs for cancer treatment

$137MSeries B

Role not disclosed